[go: up one dir, main page]

CL2011000187A1 - Preparacion farmaceutica que comprende (5-metil-2-oxo-1,3-dioxol-4il)metil 2-etoxi-1-{[2,{5-oxo-4,5-dihidro-1,2,4-oxadiazol-3-il)bifenil4il]metil}-1h-benzimidazol-7-carboxilato, un agente de control de ph entre 2 y 5 y un diuretico; metodo para estabilizar; metodo para mejorar disolucion, util en enfermedades inducidas por angiotensina ii. - Google Patents

Preparacion farmaceutica que comprende (5-metil-2-oxo-1,3-dioxol-4il)metil 2-etoxi-1-{[2,{5-oxo-4,5-dihidro-1,2,4-oxadiazol-3-il)bifenil4il]metil}-1h-benzimidazol-7-carboxilato, un agente de control de ph entre 2 y 5 y un diuretico; metodo para estabilizar; metodo para mejorar disolucion, util en enfermedades inducidas por angiotensina ii.

Info

Publication number
CL2011000187A1
CL2011000187A1 CL2011000187A CL2011000187A CL2011000187A1 CL 2011000187 A1 CL2011000187 A1 CL 2011000187A1 CL 2011000187 A CL2011000187 A CL 2011000187A CL 2011000187 A CL2011000187 A CL 2011000187A CL 2011000187 A1 CL2011000187 A1 CL 2011000187A1
Authority
CL
Chile
Prior art keywords
methyl
oxo
diuretic
control agent
dioxol
Prior art date
Application number
CL2011000187A
Other languages
English (en)
Inventor
Yutaka Nomura Junya Tanoue
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41610805&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011000187(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of CL2011000187A1 publication Critical patent/CL2011000187A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Preparación sólida que comprende un compuesto derivado de 1-(bifenil-4-ilmetil)-2-alquiloxi-1h-bnzimidazol o una sal del mismo, un agente de control de PH y un diurético; método para estabilizar dicho compuesto y un diurético en una preparación sólida; y un método para mejorar la disolución del compuesto.
CL2011000187A 2008-07-31 2011-01-28 Preparacion farmaceutica que comprende (5-metil-2-oxo-1,3-dioxol-4il)metil 2-etoxi-1-{[2,{5-oxo-4,5-dihidro-1,2,4-oxadiazol-3-il)bifenil4il]metil}-1h-benzimidazol-7-carboxilato, un agente de control de ph entre 2 y 5 y un diuretico; metodo para estabilizar; metodo para mejorar disolucion, util en enfermedades inducidas por angiotensina ii. CL2011000187A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8520108P 2008-07-31 2008-07-31
US8562708P 2008-08-01 2008-08-01

Publications (1)

Publication Number Publication Date
CL2011000187A1 true CL2011000187A1 (es) 2011-06-24

Family

ID=41610805

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011000187A CL2011000187A1 (es) 2008-07-31 2011-01-28 Preparacion farmaceutica que comprende (5-metil-2-oxo-1,3-dioxol-4il)metil 2-etoxi-1-{[2,{5-oxo-4,5-dihidro-1,2,4-oxadiazol-3-il)bifenil4il]metil}-1h-benzimidazol-7-carboxilato, un agente de control de ph entre 2 y 5 y un diuretico; metodo para estabilizar; metodo para mejorar disolucion, util en enfermedades inducidas por angiotensina ii.

Country Status (26)

Country Link
US (1) US9169238B2 (es)
EP (1) EP2310385B1 (es)
JP (1) JP5635491B2 (es)
KR (1) KR20110038145A (es)
CN (1) CN102164918B (es)
AR (1) AR072883A1 (es)
AU (1) AU2009277455A1 (es)
BR (1) BRPI0916847A2 (es)
CA (1) CA2732018C (es)
CL (1) CL2011000187A1 (es)
CO (1) CO6341633A2 (es)
CR (1) CR20110111A (es)
DO (1) DOP2011000032A (es)
EA (1) EA201170273A1 (es)
EC (1) ECSP11010856A (es)
GE (1) GEP20146062B (es)
IL (1) IL210819A0 (es)
MA (1) MA32553B1 (es)
MX (1) MX2011001150A (es)
NZ (1) NZ590948A (es)
PE (1) PE20110551A1 (es)
PT (1) PT2310385T (es)
TW (1) TW201008915A (es)
UY (1) UY32017A (es)
WO (1) WO2010013835A2 (es)
ZA (1) ZA201100871B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32126A (es) 2008-09-25 2010-04-30 Takeda Pharmaceutical Composición farmacéutica sólida
US9387249B2 (en) 2008-12-23 2016-07-12 Takeda Pharmaceutical Company Limited Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone
CN102351853B (zh) * 2011-08-29 2014-03-12 石药集团欧意药业有限公司 一种阿齐沙坦酯化合物、制备方法及其药物组合物
US20140056973A1 (en) * 2012-08-22 2014-02-27 Xenoport, Inc. Oral Dosage Forms Having a High Loading of a Methyl Hydrogen Fumarate Prodrug
JP6935301B2 (ja) * 2016-11-18 2021-09-15 花王株式会社 モノハロゲノアミン製造用被覆粒子群
IN202021028444A (es) * 2020-07-03 2022-01-28

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444769A (en) * 1982-07-27 1984-04-24 Mylan Pharmaceuticals, Inc. Antihypertensive diuretic combination composition and associated method
IL102183A (en) 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd Biphenyl substituted heterocyclic compounds their production and pharmaceutical compositions comprising them
CA2125251C (en) * 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
JP3057471B2 (ja) * 1993-06-07 2000-06-26 武田薬品工業株式会社 アンジオテンシンｉｉ介在性諸疾患の予防または治療剤
US5721263A (en) 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
CA2400845A1 (en) 2000-02-21 2001-08-23 Takeda Chemical Industries, Ltd. Sustained-release preparation of physiologically active compound slightly soluble in water and production process and use of the same
JP2001294524A (ja) 2000-04-12 2001-10-23 Taisho Pharmaceut Co Ltd アセトアミノフェン配合内服固形製剤
FR2812876B1 (fr) 2000-08-08 2002-09-27 Galderma Res & Dev Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar-gamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
EP1391200A4 (en) * 2001-05-25 2004-06-16 Ssp Co Ltd DRUG
WO2003047573A1 (en) 2001-12-03 2003-06-12 Takeda Chemical Industries, Ltd. Insulin resistance improving agents
DE10244681A1 (de) 2002-09-24 2004-04-08 Boehringer Ingelheim International Gmbh Neue feste Telmisartan enthaltende pharmazeutische Formulierungen und deren Herstellung
CA2532450C (en) 2003-07-16 2012-09-11 Boehringer Ingelheim International Gmbh Chlorthalidone combinations
US7157584B2 (en) * 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
US7625940B2 (en) 2005-07-01 2009-12-01 Accu-Break Technologies, Inc. Method of treating hypertension with a very low dose of chlorthalidone
US20080004320A1 (en) 2004-09-06 2008-01-03 Kowa Co., Ltd. Remedy for Glomerular Disease
US20070049636A1 (en) 2005-08-26 2007-03-01 Joerg Rosenberg Pharmaceutical compositions
BRPI0519656A2 (pt) * 2004-12-17 2009-03-03 Boehringer Ingelheim Int terapia de combinaÇço compreendendo telmisartan e hidroclorotiazida
US20060159747A1 (en) 2004-12-17 2006-07-20 Boehringer Ingelheim International Gmbh Telmisartan and hydrochlorothiazide combination therapy
GEP20115138B (en) 2005-03-30 2011-01-10 Takeda Pharmaceuticals Co Benzimidazole derivative and use as angiotensin ii antagonist
JP2008540573A (ja) 2005-05-13 2008-11-20 マイクロビア インコーポレーテッド ４−ビアリーリル−１−フェニラゼチジン−２−オン類
PT1897558E (pt) * 2005-06-09 2013-11-06 Norgine Bv Preparação sólida de 2-hexadeciloxi-6-metil-4h-3,1- benzoxazin-4-ona
CA2660427A1 (en) 2006-08-10 2008-02-14 Takeda Pharmaceutical Company Limited Pharmaceutical composition
WO2008045006A1 (en) 2006-10-11 2008-04-17 Fako Ilaclari A. S. Formulations of candesartan
WO2008068217A2 (en) 2006-12-04 2008-06-12 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a coated hmg-coa reductase inhibitor and an inhibitor of the renin-angiotensin system
AU2008235790B2 (en) 2007-03-28 2013-06-06 Takeda Pharmaceutical Company Limited Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent
KR20100046216A (ko) 2007-08-01 2010-05-06 테바 파마슈티컬 인더스트리즈 리미티드 칸데사르탄의 약학 조성물
US20100247649A1 (en) 2007-10-30 2010-09-30 Dr. Reddy's Laboratories Ltd. Pharmaceutical formulations comprising telmisartan and hydrochlorothiazide
US9387249B2 (en) 2008-12-23 2016-07-12 Takeda Pharmaceutical Company Limited Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone

Also Published As

Publication number Publication date
US20110123615A1 (en) 2011-05-26
CN102164918A (zh) 2011-08-24
NZ590948A (en) 2012-06-29
PE20110551A1 (es) 2011-09-02
MX2011001150A (es) 2011-03-29
WO2010013835A2 (en) 2010-02-04
PT2310385T (pt) 2017-09-11
KR20110038145A (ko) 2011-04-13
DOP2011000032A (es) 2011-02-28
EP2310385B1 (en) 2017-06-07
AU2009277455A1 (en) 2010-02-04
EA201170273A1 (ru) 2011-08-30
US9169238B2 (en) 2015-10-27
TW201008915A (en) 2010-03-01
MA32553B1 (fr) 2011-08-01
UY32017A (es) 2010-02-26
GEP20146062B (en) 2014-03-25
BRPI0916847A2 (pt) 2016-02-10
WO2010013835A3 (en) 2010-06-10
CN102164918B (zh) 2014-05-07
CA2732018C (en) 2017-07-04
ECSP11010856A (es) 2011-03-31
JP5635491B2 (ja) 2014-12-03
CO6341633A2 (es) 2011-11-21
IL210819A0 (en) 2011-04-28
AR072883A1 (es) 2010-09-29
ZA201100871B (en) 2012-05-30
JP2011529444A (ja) 2011-12-08
CA2732018A1 (en) 2010-02-04
EP2310385A2 (en) 2011-04-20
CR20110111A (es) 2011-04-28

Similar Documents

Publication Publication Date Title
CL2011000187A1 (es) Preparacion farmaceutica que comprende (5-metil-2-oxo-1,3-dioxol-4il)metil 2-etoxi-1-{[2,{5-oxo-4,5-dihidro-1,2,4-oxadiazol-3-il)bifenil4il]metil}-1h-benzimidazol-7-carboxilato, un agente de control de ph entre 2 y 5 y un diuretico; metodo para estabilizar; metodo para mejorar disolucion, util en enfermedades inducidas por angiotensina ii.
PE20130210A1 (es) Composicion farmaceutica solida que comprende un derivado de bencimidazol y un agente de control de ph
CL2007002095A1 (es) Composicion farmaceutica topica que comprende 1-(2-metilpropil)-1h-imidazo[4,5-c]quinolin-4-amina; composicion empacada; metodo para esterilizarla; util para cicatrizar tejido donde la dermis se ha desgarrado.
CL2008002354A1 (es) Forma cristalina de la sal diclorhidrato de ((1s)-1-(((2s)-2-(5-(4'-(2-((2s)-1-((2s)-2-((metoxicarbonil)amino)-3-metilbutanoil)-2-pirrolidinil)-1h-imidazol-5-il)-4-bifenilil)-1h-imidazol-2-il)-1-pirrolidinil)carbonil)-2-metilpropil)carbamato de metilo; composición y combinacion farmacéutica; y su uso para tratar la hepatitis c.
BR112013032122A2 (pt) liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos
CL2011000625A1 (es) Preparación sólida que comprende 2-etoxi-1-((2'-(5-oxo-4,5-dihidro-1,2,4-oxadiazol-3-il)bifenil-4-il)metil)-1h-bencimidazol-7-carboxilato de (5-metil-2-oxo-1,3-dioxol-4-il)metilo, un agente regulador de ph y un compuesto antagonista de calcio; y metodos para utilizar y mejorar disolucion del compuesto en la preparacion solida.
UY32062A (es) Inhibidores de beta-secretasa
CL2007002228A1 (es) Composicion farmaceutica topica que comprende 1-(2-metilpropil)-1h-imidazo[4,5-c]quinolin-4-amina; composiicon empacada; metodos para esterelizarlas; util para cicatrizar tejido donde la dermis se ha desgarrado.
CL2012003654A1 (es) Formulación farmaceutica estable para administracion intratecal que comprende una proteina arilsulfatasa a (asa), sal y un tensoactivo de polisorbato y/o un agente amortiguador, y que ademas puede contener un agente estabilizante; contenedor que comprende dicha formulacion; uso para tratar la enfermedad leucodistrofia metacromática (mld).
BR112012020731A2 (pt) pastilhas gelatinosas suaves com nicotina.
RU2012157473A (ru) Способ выявления или лечения реакции "трансплантат против хозяина"
NO20091767L (no) Mikropumpe-operert medisindoseringssystem
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
BRPI0718523B8 (pt) Forma de dosagem, e, método para preparar a forma de dosagem
HRP20100616T1 (hr) Derivati benzimidazola i njihova uporaba za modulaciju gabaa receptorskog kompleksa
CL2007001457A1 (es) Preparacion oral que comprende pioglitazona o una sal de la misma y un cloruro de metal alcalino, util como hipoglicemiante.
WO2008128775A3 (en) Stabilised pharmaceutical composition containing pregabaline
CL2011000135A1 (es) Uso de una fromulacion farmaceutica acuosa que comprende 0,5-10% de terbinafina o una sal de la misma, 2-10% de un fosfolipido y 1-5% de un surfactante, para preparar un medicamento util para tratar una infeccion fungica; formulacion farmaceutica.
MX389961B (es) Dispersiones sólidas que comprenden estimulador de heme guanilato ciclasa soluble (sgc).
AU2007270125A8 (en) Preservation and controlled delivery/release of spermatozoa
PE20081751A1 (es) Composicion farmaceutica que comprende un antagonista muscarinico y antagonista beta-2 adrenorreceptor
AR063538A1 (es) Tratamiento de la enfermedad de parkinson
MY146947A (en) Antiparasitic agent for fish and method of controlling proliferation of fish parasites
EA201390335A1 (ru) Введение лоркасерина индивидуумам с почечной недостаточностью
EP2279726A3 (en) Compositions and methods using same for delivering agents into a target organ protected by a blood barrier